Alnylam Pharmaceuticals, Inc. (ALNY) Stock Analysis
Is ALNY a good investment?
Alnylam Pharmaceuticals, Inc. (ALNY) has a Plutrex AI rating of 85.0/100 as of July 11, 2026, indicating a Strong Buy consensus. The stock is not classified as halal-compliant. Key strength: PEG ratio of 0.38x (vs. industry 1.10x) signals 65.5% growth-adjusted undervaluation — 5-year EPS CAGR of 78.3% is 213% above the biotech industry average of 24.98%, making ALNY the sector's premier growth-adjusted value; analyst consensus target of $439.92 implies 40.6% upside from $312.78. Main concern: Elevated leverage UNCHANGED: D/E ratio of 2.51x (vs. industry average 0.60x — 318% above peers) creates financial vulnerability if Amvuttra revenue growth decelerates or credit conditions tighten; FCF of $204.7M is modest relative to implied debt load, limiting organic deleveraging; $3.0B cash partially mitigates but does not eliminate this structural risk.
Investment Summary
Alnylam Pharmaceuticals (ALNY) at $312.78 remains a compelling high-conviction Buy, anchored by a PEG ratio of 0.38 (vs. industry average 1.10x — a 65.5% discount on growth-adjusted basis), 5-year forward EPS CAGR of 78.3% (213% above the biotech industry average of 24.98%), and an analyst consensus target of $439.92 implying 40.6% upside. The stock has appreciated 7.3% since the prior report ($291.37 → $312.78), narrowing but not eliminating the margin of safety. Profitability is exceptional: gross margin 80.8%, operating margin 23.0%, ROE 96.9% — all dramatically above a biotech peer group averaging deeply negative margins. The primary concern remains elevated leverage (D/E 2.51x vs. industry average 0.60x), partially offset by $3.0 billion in cash and $204.7 million in positive free cash flow. News sentiment is near-perfect at 95.6/100 with 11 positive and 0 negative headlines, including the Komodo AI partnership expansion and ALN-6400 pipeline development. The investment thesis is materially unchanged from the prior report — ALNY is a rare profitable, high-growth biotech trading at a significant discount to its growth-adjusted intrinsic value.
Key Strengths
- PEG ratio of 0.38x (vs. industry 1.10x) signals 65.5% growth-adjusted undervaluation — 5-year EPS CAGR of 78.3% is 213% above the biotech industry average of 24.98%, making ALNY the sector's premier growth-adjusted value; analyst consensus target of $439.92 implies 40.6% upside from $312.78
- Exceptional profitability unmatched in biotech: gross margin 80.8% vs. industry average -3.8%, operating margin 23.0% vs. industry average -2,047%, ROE 96.9% vs. industry average -34.2% — ALNY generates real earnings while virtually all biotech peers burn cash, supported by $3.0B cash and $204.7M positive FCF
- Near-perfect news execution at 95.6/100 sentiment with 11 positive and 0 negative headlines: Komodo AI partnership expansion accelerating commercial intelligence, ALN-6400 RNAi therapy pipeline broadening beyond Amvuttra concentration, Wall Street analysts confirming 45%+ upside thesis, and momentum designation reinforcing institutional confidence
Key Concerns
- Elevated leverage UNCHANGED: D/E ratio of 2.51x (vs. industry average 0.60x — 318% above peers) creates financial vulnerability if Amvuttra revenue growth decelerates or credit conditions tighten; FCF of $204.7M is modest relative to implied debt load, limiting organic deleveraging; $3.0B cash partially mitigates but does not eliminate this structural risk
- Amvuttra revenue concentration combined with P/E of 74.32x (59.4% premium to industry average 46.62x): any pipeline setback, Amvuttra sales miss, or competitive entry could trigger multiple compression; headline 'Can Alnylam's Broader Portfolio Ease Its Dependence on Amvuttra?' remains an open question, though ALN-6400 pipeline expansion and Komodo AI partnership suggest management is actively addressing diversification
Plutrex 10-Factor AI Breakdown
Fundamental Analysis
ALNY's fundamentals remain exceptional and unchanged from the prior report. Gross margin of 80.8% reflects strong pricing power from its proprietary RNAi platform — this is a structural competitive moat. Operating margin of 23.0% is remarkable for a biotech that continues to invest heavily in R&D. Net margin of 13.5% is meaningfully below operating margin, confirming substantial interest expense from the D/E of 2.51x (vs. industry 0.60x). ROE of 96.9% is leverage-amplified but still reflects genuine capital efficiency — the underlying business generates outstanding returns. The PEG ratio of 0.38 (slightly up from 0.35 prior, driven by stock price appreciation of 7.3% with the analyst target essentially flat at $439.92 vs. prior $441.58) remains the definitive valuation signal: investors pay only 38 cents per dollar of expected growth. The P/E of 74.32x appears elevated in isolation but is fully justified by the 78.3% 5-year EPS CAGR. Cash of $3.009 billion provides substantial liquidity. FCF of $204.7 million is positive and growing. Revenue growth of 96.4% YoY confirms successful commercial scaling. The primary financial risk is the D/E of 2.51x — elevated leverage that creates vulnerability if Amvuttra revenue growth decelerates or credit conditions tighten.
News Sentiment
Alnylam Pharmaceuticals is firing on all cylinders, and Wall Street is taking notice. The Boston-based biotech — which has quietly built one of the most profitable drug platforms in the industry — is generating buzz across multiple fronts that suggest its best days may still be ahead. Analysts are bullish, with one headline declaring 'Wall Street Thinks This Biotech Stock Can Soar 45%' — and the math backs it up. With six marketed therapies already generating revenue and a pipeline that keeps expanding, Alnylam is no longer just a one-trick pony. The company is actively working to reduce its dependence on its blockbuster Amvuttra therapy, as highlighted by coverage asking 'Can Alnylam's Broader Portfolio Ease Its Dependence on Amvuttra?' — and the answer appears to be yes. The company's newest pipeline candidate, ALN-6400, an RNAi therapy targeting a novel mechanism, is generating early excitement. While still in early stages, rare disease designation potential could fast-track regulatory approval and lock in market exclusivity — a significant competitive advantage. Perhaps most intriguing is Alnylam's expanding partnership with Komodo Health, which is scaling AI-powered intelligence to sharpen drug discovery and commercial strategy. The deal leverages artificial intelligence to accelerate RNA-based medicine development — potentially compressing timelines that typically take years. For everyday investors, the story is straightforward: a profitable biotech with a proven drug platform, a growing pipeline, and smart technology partnerships — trading at a significant discount to what analysts think it's worth.
Risk Assessment
PRIMARY RISK: Amvuttra revenue concentration — if the flagship therapy misses sales expectations or faces competitive entry, the high P/E of 74.32x provides no fundamental floor and multiple compression could be severe. SECONDARY RISK: Elevated leverage (D/E 2.51x vs. industry 0.60x) amplifies downside in adverse scenarios; FCF of $204.7M limits organic deleveraging pace, though $3.0B cash provides a meaningful buffer. TERTIARY RISK: PEG of 0.38 is predicated on 78.3% 5-year EPS CAGR — any material pipeline failure or pricing pressure that resets this growth assumption would invalidate the undervaluation thesis. MITIGATION: Stop loss at $280 (approximately 10.5% below entry midpoint of $310) limits downside; $3.0B cash position provides near-term solvency protection; Komodo AI partnership and ALN-6400 pipeline development represent active diversification efforts; analyst consensus of $439.92 with 40.6% upside provides a 4.3:1 risk-reward ratio at entry.
Related Halal Stocks
Related Stocks
Frequently Asked Questions
Is ALNY a halal stock?
No, Alnylam Pharmaceuticals, Inc. (ALNY) is currently not classified as halal by AAOIFI criteria.
What is Plutrex's AI rating for ALNY?
Alnylam Pharmaceuticals, Inc. (ALNY) has a Plutrex AI rating of 85.0/100 with a Strong Buy consensus, based on a 10-factor analysis covering financial health, growth, valuation, profitability, debt, analyst sentiment, technical momentum, insider confidence, news sentiment, and halal compliance.
Is ALNY a good investment?
According to Plutrex AI, ALNY has a Strong Buy rating (85.0/100). For the full analysis including trading plan and risk assessment, see the detailed breakdown above.
How can I invest in ALNY?
US stocks like ALNY can be bought through international brokers such as Interactive Brokers, accessible to Arab investors. Plutrex provides comprehensive analysis plus AI-generated trading plans with entry points, stop losses, and profit targets.
What are the main risks of investing in ALNY?
Plutrex AI identifies the main risks for ALNY by analyzing valuation, debt, market sentiment, and macro factors. See the Risk Assessment section above for the full breakdown.